FDA Approves Tislelizumab Plus Chemotherapy for PD-L1+ Metastatic Esophageal Cancer

CHMP Recommends Durvalumab Combination for EU Approval in Resectable NSCLC

Enhertu Gains EMA’s CHMP Support for HER2-Low Metastatic Breast Cancer Treatment

KEYTRUDA Receives Priority FDA Review for Perioperative Use in ES Head and Neck Cancer

Odronextamab Gains FDA Review for Hard-to-Treat R/R Follicular Lymphoma

FDA Approves Innovative ADC Datroway for Metastatic HR+, HER2- Breast Cancer

FDA Approves Sotorasib and Panitumumab Combo for KRAS G12C+ Colorectal Cancer

FDA Approves 225Ac-SSO110 Radiopharmaceutical Trial for Small Cell Lung Cancer

FDA Grants Priority Review to Datopotamab Deruxtecan for EGFR+ Lung Cancer

First-Ever Obstructive Sleep Apnea Drug, Zepbound, Approved by FDA for Obesity

FDA Approves BRAFTOVI Combo as First-Line Treatment for Colorectal Cancer

FDA Grants Breakthrough Status to Datopotamab Deruxtecan for EGFR+ Lung Cancer

Promising Sac-TMT Receives FDA Breakthrough Therapy Designation for Lung Cancer

Durvalumab Granted FDA Priority Review for Muscle-Invasive Bladder Cancer Patients

FDA Approves Durvalumab as the First and Only Immunotherapy for LSSC Lung Cancer

FDA Grants Accelerated Approval to Bizengri for NRG1+ Pancreatic Cancer and NSCLC

The FDA Approves IMKELDI, the First Oral Liquid Form of Imatinib, for Leukemia

FDA Approves First Targeted Therapy for IDH-Mutant Glioma with Companion Diagnostic

FDA Approves VYLOY™ as a New Targeted Therapy for Advanced Gastric and GEJ Cancer

AI-Powered Cancer Drug LP-184 Receives FDA Fast-Track Designation for Glioblastoma

FDA Approves TruSight Cancer Test for Matching Patients with Targeted Therapies

Nipocalimab Submitted to FDA for Treatment of Generalized Myasthenia Gravis

Novel Cancer Drug PT217 Wins FDA Orphan Drug Status for Neuroendocrine Carcinoma

Mixed-Reality System, HipInsight, Receives FDA Approval for Hip Surgery

FDA Approves Neffy: First Nasal Spray for Emergency Allergic Reactions

Iptacopan, the First CI, Wins FDA Accelerated Approval for IgA Nephropathy

FDA Approves Vorasidenib as First Targeted Therapy for G2 IDH-Mutant Glioma

FDA Approves Expanded Use of Dostarlimab for Treatment of Endometrial Cancers

FDA Approves Johnson's Daratumumab Plus VRd for Newly Diagnosed Multiple Myeloma

FDA Approves Expanded Use of Xembify for Immunodeficiency Treatment